

# lifetimeRisk: An R package for lifetime risk analysis with competing risks

Matthew W. Segar<sup>1</sup>, Byron C. Jaeger<sup>2</sup>, and Ambarish Pandey<sup>3</sup>

<sup>1</sup> Department of Cardiology, Texas Heart Institute, Houston, TX <sup>2</sup> Perisphere Real World Evidence LLC, Austin, Texas <sup>3</sup> Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX ¶ Corresponding author

DOI: [10.xxxxxx/draft](https://doi.org/10.xxxxxx/draft)

## Software

- Review
- Repository
- Archive

Editor: [Open Journals](#)

## Reviewers:

- @openjournals

Submitted: 01 January 1970

Published: unpublished

## License

Authors of papers retain copyright and release the work under a Creative Commons Attribution 4.0 International License ([CC BY 4.0](#))

## Summary

Lifetime risk estimation is fundamental to understanding long-term disease burden and provides important insights for epidemiologists and clinicians assessing population health across diverse medical domains. The `lifetimeRisk` package provides tools for calculating lifetime risk of adverse outcomes while properly accounting for competing risks, implementing the methodology established by the SAS Practical Incidence Estimators (PIE) macro (Beiser et al., 2000). Originally developed for Alzheimer's disease research in the Framingham Study, the PIE macro provides a widely-used framework for lifetime risk calculations across epidemiological research, from cardiovascular disease and cancer to dementia and chronic diseases. The package enables person-year calculations, age-specific incidence rates, cumulative incidence with competing risks, and age-adjusted rates using the same statistical algorithms as the original PIE macro. All statistical computations have been validated against the reference SAS implementation to ensure methodological consistency and numerical equivalence for research applications.

## Statement of need

Lifetime risk analysis extends traditional short-term risk assessment and has influenced medical research and clinical practice across multiple disciplines. The fundamental challenge addressed by lifetime risk methodology is that conventional 10-year risk models often underestimate long-term disease burden, particularly in younger populations who may face substantial cumulative risk despite appearing low-risk in short-term assessments. The statistical complexity lies in properly accounting for competing risks, where multiple potential outcomes can preclude the occurrence of the primary endpoint of interest. This is particularly relevant in aging populations where cardiovascular disease, cancer, and other-cause mortality compete as terminal events.


The impact of this methodology is evident in cardiovascular epidemiology, where lifetime risk studies have changed understanding of disease burden and clinical decision-making. Landmark studies by Lloyd-Jones et al. and Berry et al. demonstrated marked differences in lifetime cardiovascular disease risks across racial groups (Berry et al., 2012; Lloyd-Jones et al., 1999). These studies, along with subsequent publications demonstrating lifetime risks exceeding 30% even for individuals with optimal risk factors (Wilkins et al., 2012) and significant differences across sex-based groups (Pandey et al., 2018), have established lifetime risk as important for clinical decision-making and population health assessment.

Despite widespread use of these methods in high-impact research, accessible implementations have been limited. While R packages such as `survival`, `cmprsk`, and `etm` provide foundational competing risks methods, none offer the lifetime risk calculation framework with standardized output formats established by the PIE macro. The `lifetimeRisk` package fills this gap by providing an R implementation of the PIE macro methodology and enables researchers to



Dataset Size	Median Time (seconds)	Memory Usage (MB)	Observations per Second
25,000	0.54	1.0	46,167
50,000	0.88	1.9	56,714
100,000	1.64	3.8	61,024
1,000,000	14.44	38.1	69,269

82 *Note: Benchmarks performed using microbenchmark package with 5 replications per dataset*  
83 *size on standard computing hardware.*



**Figure 1:** Example output from the 'lifetimeRisk' package demonstrating (A) summary statistics for sex-stratified lifetime risk analysis showing final cumulative incidence estimates, and (B) competing risks-adjusted cumulative incidence curves illustrating lifetime risk trajectories between men and women from age 45 to 90 years, with shaded confidence bands indicating 95% confidence intervals.

84 The package provides a function library designed for both novice and expert users. Key  
85 functions include `pie_analysis()` for complete lifetime risk analysis implementing the full PIE  
86 macro methodology, `calculate_age_specific_rates()` for detailed age-stratified incidence  
87 computations, `calculate_cumulative_incidence()` for competing risks-adjusted cumulative  
88 incidence calculation (**Figure 1A**), and specialized visualization and export functions. The  
89 `plot_lifetime_risk()` function generates publication-ready graphics with customizable con-  
90 fidence intervals (**Figure 1B**), while `create_lifetime_risk_table()` produces standardized  
91 summary tables suitable for manuscript inclusion.

## 92 Research applications and impact

93 The lifetimeRisk package addresses a need in epidemiological research for a freely accessible,  
94 open-source implementation of life time risk methodology, which has been widely cited in  
95 epidemiological literature and has influenced clinical practice guidelines. The package has been  
96 successfully applied in cardiovascular epidemiology research, including our recent multicohort  
97 study examining P-wave parameters and lifetime atrial fibrillation risk (Segar et al., 2025). In  
98 this analysis of 25,508 participants from 4 prospective cohort studies, we used the lifetimeRisk  
99 package to demonstrate that participants with multiple ECG abnormalities had lifetime AF risks  
100 reaching 35.7% compared to 22.9% for those with minimal abnormalities, with participants  
101 having 4+ ECG abnormalities living an average of 17.1 years free of AF compared to 21.7  
102 years for those with none. This application demonstrates the package's capability to handle  
103 large-scale multicohort analyses and produce clinically meaningful lifetime risk estimates that  
104 inform patient care and risk stratification.

The broad applicability of lifetime risk methods extends across medical specialties. Cancer epidemiologists have used these approaches to develop global estimates of lifetime cancer risk, while neurological research has employed lifetime risk calculations to understand dementia patterns. Public health researchers have applied the methodology to examine health disparities and assess long-term health impacts of exposures. Recent applications demonstrate continued relevance, including population-specific lifetime risk tools and comprehensive models for diverse populations.

The `lifetimeRisk` package facilitates these research applications by providing a documented platform that removes technical barriers to implementing lifetime risk analyses. The package includes documentation, worked examples across different research domains, and flexible functions that accommodate various study designs and research questions, enabling researchers without extensive statistical programming backgrounds to apply these methods to their research.

## Acknowledgements

This implementation builds upon the foundational statistical methodology established by Beiser et al. in the original SAS PIE macro and acknowledges the extensive validation and application work conducted in landmark epidemiological studies. We recognize the impact of this methodology on epidemiological research and clinical practice across medical disciplines.

## References

- Beiser, A., D'Agostino Sr, R. B., Seshadri, S., Sullivan, L. M., & Wolf, P. A. (2000). Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the framingham study: The practical incidence estimators (PIE) macro. *Statistics in Medicine*, 19(11), 1495–1522. [https://doi.org/10.1002/\(SICI\)1097-0258\(20000615\)19:11%3C1495::AID-SIM441%3E3.0.CO;2-E](https://doi.org/10.1002/(SICI)1097-0258(20000615)19:11%3C1495::AID-SIM441%3E3.0.CO;2-E)
- Berry, J. D., Dyer, A., Cai, X., Garside, D. B., Ning, H., Thomas, A., Greenland, P., Van Horn, L., Tracy, R. P., & Lloyd-Jones, D. M. (2012). Lifetime risks of cardiovascular disease. *New England Journal of Medicine*, 366(4), 321–329. <https://doi.org/10.1056/NEJMoa1012848>
- Fine, J. P., & Gray, R. J. (1999). A proportional hazards model for the subdistribution of a competing risk. *Journal of the American Statistical Association*, 94(446), 496–509. <https://doi.org/10.1080/01621459.1999.10474144>
- Lloyd-Jones, D. M., Larson, M. G., Beiser, A., & Levy, D. (1999). Lifetime risk of developing coronary heart disease. *The Lancet*, 353(9147), 89–92. [https://doi.org/10.1016/S0140-6736\(98\)10279-9](https://doi.org/10.1016/S0140-6736(98)10279-9)
- Pandey, A., Omar, W., Ayers, C., LaMonte, M., Klein, L., Allen, N. B., Kuller, L. H., Greenland, P., Eaton, C. B., Gottdiener, J. S., & others. (2018). Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. *Circulation*, 137(17), 1814–1823. <https://doi.org/10.1161/CIRCULATIONAHA.117.031622>
- Segar, M. W., Lambeth, K., Rosenblatt, A., Razavi, M., Pandey, A., & Saeed, M. (2025). Electrocardiographic p-wave parameters and lifetime atrial fibrillation risk: A multicohort study. *Heart Rhythm*. <https://doi.org/10.1016/j.hrthm.2025.02.308>
- Wilkins, J. T., Ning, H., Berry, J., Zhao, L., Dyer, A. R., & Lloyd-Jones, D. M. (2012). Lifetime risk and years lived free of total cardiovascular disease. *JAMA*, 308(17), 1795–1801. <https://doi.org/10.1001/jama.2012.14312>